Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -125K | 0 | 0 | 0 | 0 |
| Operating Income | -40M | -30M | -25M | -15M | -11M |
| EBITDA | -40M | -30M | -25M | -15M | -10M |
| Net Income | -36M | -27M | -24M | -15M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.56
-2.78% today
1Y Change
-2.92%
Window
Jun 26, 2025 → Jun 18, 2026
Coverage: 246 bars · Jun 26, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Context Therapeutics Inc. (CNTX) is a Healthcare stock with a market cap of $220.00M and listed on NASDAQ. The stock last traded around $0.56 and down 2.9% across the available one-year price window (Jun 26, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +17.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +17.4%, free cash flow +9.9% with operating margin 0.0% and ROIC -65.5%. Stock Foundry combines CNTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CNTX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CNTX Max Drawdown
-82.14%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CNTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$10.5M
+29.5% YoY
Free Cash Flow
-$9.0M
+35.8% YoY
Revenue Growth
+0.0%
EPS Growth
+17.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -125K | 0 | 0 | 0 | 0 |
| Operating Income | -40M | -30M | -25M | -15M | -11M |
| EBITDA | -40M | -30M | -25M | -15M | -10M |
| Net Income | -36M | -27M | -24M | -15M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 66M | 94M | 14M | 35M | 50M |
| Total Assets | 68M | 98M | 16M | 38M | 51M |
| Total Liabilities | 8M | 3M | 4M | 3M | 3M |
| Shareholder Equity | 60M | 95M | 12M | 35M | 48M |
| Total Debt | 112K | 219K | 0 | 55K | 0 |
| Net Debt | -66M | -94M | -14M | -35M | -50M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
+35.1% YoY
Capital Expenditures
250K
+53.4% YoY
Free Cash Flow
9M
+35.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.